Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Colitis, Ulcerative × Lymphoid × 30 days × Clear all

Status

Active not recruiting 1

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Other hematologic neoplasm 1 Lymphoid 1

Conditions

Lymphoma 109 Precursor Cell Lymphoblastic Leukemia-Lymphoma 92 Lymphoma, Non-Hodgkin 88 Leukemia, Lymphocytic, Chronic, B-Cell 81 Lymphoma, Follicular 76 Lymphoma, Large B-Cell, Diffuse 75 Burkitt Lymphoma 45 Leukemia, Myeloid, Acute 43 Lymphoma, Mantle-Cell 42 Lymphoma, B-Cell 41 Hodgkin Disease 37 Recurrence 36 Lymphoma, B-Cell, Marginal Zone 33 Multiple Myeloma 30 Leukemia 29 Neoplasms 28 Hematologic Neoplasms 28 Waldenstrom Macroglobulinemia 23 Myelodysplastic Syndromes 22 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 19 Lymphoma, T-Cell, Peripheral 15 Leukemia, Biphenotypic, Acute 14 Lymphoproliferative Disorders 13 Lymphoma, T-Cell 13 Melanoma 11 Lymphoma, Large-Cell, Anaplastic 11 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 11 Breast Neoplasms 11 Leukemia, B-Cell 10 Myeloproliferative Disorders 9

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02808780 2026-03-13

OPAL

Janssen Biotech, Inc.

Active not recruiting

Colitis, Ulcerative, Lymphoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡